Get the Stockscreener App
17.04
0.53%
0.09
After Hours:
17.04
Nurix Therapeutics Inc stock is traded at $17.04, with a volume of 2.68M.
It is up +0.53% in the last 24 hours and up +7.47% over the past month.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
See More
Previous Close:
$16.95
Open:
$17.15
24h Volume:
2.68M
Relative Volume:
1.61
Market Cap:
$1.76B
Revenue:
$71.78M
Net Income/Loss:
$-295.28M
P/E Ratio:
-5.3929
EPS:
-3.1597
Net Cash Flow:
$-271.85M
1W Performance:
+8.95%
1M Performance:
+7.47%
6M Performance:
-10.36%
1Y Performance:
+42.83%
1-Day Range:
$16.80
$17.87
1-Week Range:
$14.67
$18.91
52-Week Range:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.04 | 1.75B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination - news.financial
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Nurix surges 43% on up to $3B cancer drug deal with Roche - MSN
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
BTIG Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy - Investing News Network
Nurix (NRIX) presents updated Bexobrutideg data at EHA 2026 - grafa.com
H.C. Wainwright reiterates Nurix stock rating on Roche deal - Investing.com UK
Nurix reports updated clinical data for CLL drug candidate - Investing.com UK
Nurix Therapeutics Deal With Roche Is Worth Betting On (NASDAQ:NRIX) - Seeking Alpha
Nurix Highlights Promising Phase 1b Data for Bexobrutideg - TipRanks
Nurix Therapeutics reports Phase 1a/1b update: 83% ORR, 22.1-month median PFS; 600 mg RP2D well tolerated - TradingView
Nurix (NASDAQ: NRIX) shows high CLL response rates in bexobrutideg Phase 1 - Stock Titan
Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy - TradingView
Experimental BTK degrader sees 83% response in relapsed CLL - Stock Titan
NRIX Reiterates Buy Rating by HC Wainwright & Co. -- Price Targe - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Amova Asset Management Americas Inc. Has $24.48 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
NRIX Maintained by Truist Securities -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Inc. (NRIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Sahm
NRIX Maintained by BTIG -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Price Target Raised to $32.00/Share From $30.00 by Truist Securities - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions - Seeking Alpha
BTIG Research Increases Nurix Therapeutics (NASDAQ:NRIX) Price Target to $32.00 - MarketBeat
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Jefferies raises Nurix stock price target on Roche partnership By Investing.com - Investing.com Australia
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated DiseasesSlideshow (NASDAQ:NRIX) 2026-06-09 - Seeking Alpha
Nurix stock gets Outperform rating reiterated by RBC Capital By Investing.com - Investing.com Australia
Nurix Therapeutics Inc to Host Investor Update Call Transcript - GuruFocus
Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - MSN
Nurix Therapeutics (NRIX) Stock Soars 24% on Roche Collaboration Announcement - GuruFocus
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics - MSN
NRIX Maintained by Wells Fargo -- Price Target Lowered to $25 - GuruFocus
NRIX Maintained by Jefferies -- Price Target Raised to $45 - GuruFocus
NRIX Maintained by Needham -- Price Target Raised to $34 - GuruFocus
Roche's $2.3 Billion Nurix Deal Sends Shares Moving - GuruFocus
Nurix signs 4th and largest partnership to develop BTK degrader - BioWorld News
Roche Partners with Nurix (NRIX) for $2.3 Billion Blood Cancer D - GuruFocus
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying - Investor's Business Daily
Roche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical Executive
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaborati - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $25.00 at Wells Fargo & Company - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
NRIX Stock Slides As Traders Parse Insider Filing - timothysykes.com
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):